Potential of high-dose cefepime/tazobactam against multi-resistant Gram-negative pathogens by Livermore, David M et al.
Potential of high-dose cefepime/tazobactam against multi-resistant Gram-negative pathogens 1 
 2 
 3 
David M LIVERMORE1,2*, Shazad MUSHTAQ2, Marina WARNER2, Simon J TURNER3 and Neil 4 
WOODFORD2 5 
 6 
Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 2Antimicrobial 7 
Resistance and Healthcare Associated Infections Reference Unit, Public Health England National 8 









Running Head : Potential of cefepime/tazobactam 18 
 19 
 20 
*Corresponding author 21 
 22 
Prof. David M Livermore 23 
Floor 2, Bob Champion Research & Educational Building, 24 
James Watson Road, 25 
University of East Anglia, 26 
Norwich Research Park,  27 
NORWICH, NR4 7UQ 28 
 29 
Tel: +44(0)-1603-597-568 30 
d.livermore@uea.ac.uk / david.livermore@phe.gov.uk 31 
 32 
33 
Background: Early -Lactamase inhibitors were combined with established penicillins, but different 34 
combinations may be more appropriate to current -lactamase threats, with development facilitated by 35 
the US GAIN (Generating Antibiotic Incentives Now) Act. Cefepime/tazobactam is especially attractive, 36 
combining an AmpC-stable cephalosporin with a clinically established inhibitor, active against ESBLs 37 
and suitable for high-dose administration.  38 
Materials/methods: Organisms (n=563) were clinical isolates submitted to the UK national reference 39 
laboratory.  MICs were determined by CLSI agar dilution with tazobactam at 4 mg/L and, for a subset, 40 
at 8 mg/L.  41 
Results: Cefepime/tazobactam 8+4 mg/L achieved coverage of 96-100% of Enterobacteriaceae with 42 
penicillinases, AmpC, ESBL, K1 or OXA-48 -lactamases.  Even at 1+4 mg/L, the combination inhibited 43 
>94% of isolates with penicillinases, AmpC enzymes or ESBLs.  Most Enterobacteriaceae with KPC 44 
and NDM carbapenemase were resistant at current cefepime breakpoints but 80% of those with VIM 45 
types were susceptible at 8+4 mg/L.  Tazobactam did little to potentiate cefepime against non-fermenter 46 
groups, though gains were seen against AmpC-producing Acinetobacter spp. and Stenotrophomonas 47 
maltophilia.  Increasing the tazobactam concentration to 8 mg/L gave further small increases in activity 48 
against Enterobacteriaceae groups. 49 
Conclusions: High-dose cefepime/tazobactam, justifying an 8+4 or 8+8 mg/L, breakpoint, would 50 
achieve a carbapenem-like spectrum, with some additional coverage of OXA-48 (and maybe VIM) 51 
Enterobacteriaceae.  Clinical evaluation is warranted. 52 
53 
Introduction 54 
The 1970s and early 80s saw two strategies to overcome acquired penicillinases, then already prevalent 55 
in Gram-negative bacteria. Many companies developed ‘-lactamase-stable’ oxyimino-cephalosporins 56 
whilst a few developed -lactamase inhibitors to protect existing penicillins.  Both approaches achieved 57 
some success, though resistance accumulated over time.  By the late 1980s, ESBLs were already 58 
eroding oxyimino cephalosporin utility, and have since proliferated greatly.1  Meanwhile, the penicillins 59 
used in inhibitor combinations – particularly amoxicillin and ticarcillin – proved challenging to protect 60 
owing to their extreme lability, and resistance is frequent in bacteria that have multiple or copious -61 
lactamases.2  It was quickly recognised that clavulanate and tazobactam could protect oxyimino 62 
cephalosporins against ESBLs, with MICs often reduced far below those of the penicillins used in clinical 63 
combinations. This behaviour is exploited in ESBL detection tests1 but not in clinical combinations. With 64 
(i) oxyimino-cephalosporin and inhibitor patents owned by different companies and eroding in parallel 65 
and (ii) the general challenges of antibacterial development and commercialization,3 there was little 66 
scope or business incentive for development of combinations of soon-to-be-generic agents. Moreover, 67 
most prospective cephalosporin-inhibitor combinations failed to cover bacteria with hyperproduced 68 
AmpC enzymes, making them less attractive than carbapenems, which evade both AmpC and ESBL 69 
enzymes. Cefepime-inhibitor combinations were the obvious exception, given cefepime's stability to 70 
AmpC,4 but cefepime's sponsors took the view that their molecule was adequately active against many 71 
ESBL strains at CLSI’s then breakpoints (S <8, R >16 mg/L) and did not need protection with an 72 
inhibitor. The fact that this breakpoint was too high for the commonly-used 1g twice daily regimen only 73 
gradually achieved acceptance, as clinical failures were reported against ESBL strains with MICs of 2-74 
4 mg/L.5  EUCAST6 adopted S <1, R >4mg/L breakpoints, and CLSI later lowered their susceptible 75 
breakpoint to <2, with MICs of 4-8 mg/L considered susceptible to higher and/or more frequent doses.7   76 
Another shift was that the TEM and SHV ESBLs, often conferring only modest rises in cefepime MICs, 77 
were supplanted by CTX-M-15, typically conferring substantive resistance.8,9   78 
We previously showed that cefepime-clavulanate was widely active in vitro against 79 
Enterobacteriaceae with ESBLs and AmpC enzymes.4 Subsequent interest has concentrated on 80 
cefepime/tazobactam, based on tazobactam being more chemically stable than clavulanate, easier to 81 
manufacture, less likely to induce AmpC,2 and better-tolerated at high dosage (up to 2g thrice daily, by 82 
90 min infusion, for 7 days, in combination with equal amounts of cefepime).10    83 
Several cefepime/tazobactam combinations are marketed in India,11 with positive case series 84 
described.12 A trial in urinary tract infection, with or without concurrent genitourinary tract pathology, 85 
reported 93.3% clinical cure.13 However all these combinations retain an 8:1 cefepime:tazobactam ratio, 86 
as for piperacillin/tazobactam, meaning that even the maximal 2 + 0.25g thrice daily regimen delivers 87 
only 0.75g tazobactam per day. This is low compared with 1.5g exposure used in recently-licensed 88 
ceftolozane/tazobactam, which uses a strongly antipseudomonal cephalosporin that lacks cefepime’s 89 
stability to enterobacterial AmpC.14  90 
Legislation to encourage the repurposing and reformulating of old antibiotics, notably the US 91 
Generating Antimicrobial Incentives Now (GAIN) Act, may give commercial viability to the development 92 
of cefepime with high-dose tazobactam, and we explored this potential of this combination using panels 93 
of characterised organisms. 94 
 95 
Methods and materials 96 
Bacteria 97 
Organisms (n=593) were recent clinical submissions to the UK national reference laboratory 98 
(Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, AMRHAI, at PHE 99 
Colindale, London).   Bacterial identification was by MALDI-ToF (Bruker Daltonics, Bremen, Germany), 100 
and carbapenemase genes (blaIMP, blaKPC, blaIMP, blaNDM, blaOXA-48-like, blaVIM) were detected by PCR;15 101 
other mechanisms were inferred by interpretive reading of phenotypes.16 The species distribution of 102 
Enterobacteriaceae isolates representing different resistance mechanisms is shown in Table 1.  None 103 
of these species is inherently resistant to cefepime or any comparator tested.   104 
 105 
Susceptibility testing 106 
MICs of cefepime  were determined by CLSI agar dilution17 with tazobactam at 0 and 4 mg/L; 107 
comparators were piperacillin with tazobactam 4 mg/L and ceftazidime (all Sigma, Poole, UK) and 108 
meropenem (Sequoia, Pangbourne, UK).  MICs of cefepime with 8 mg/L tazobactam were determined 109 
for a sub-set of the isolates.   110 
 Given the differences in EUCAST and CLSI breakpoints for cefepime, and the lack of current 111 
guidance for cefepime/tazobactam we reviewed data against a ‘most conservative’ breakpoint of 112 
cefepime/tazobactam 1+4 mg/L, predicated upon EUCAST’s current 1 mg/L susceptibility breakpoint 113 
for unprotected cefepime and a ‘most liberal’ value of 8+4 mg/L based upon the upper bound of CLSI’s 114 
‘Dose Dependent Susceptibility’ category.17  The ultimate breakpoint for any commercial 115 




Irrespective of the presence of tazobactam, cefepime was universally active against control and 120 
penicillinase-producing Enterobacteriaceae at 1 mg/L; it was also active against 81.3% of the AmpC 121 
producers at 1 mg/L, rising to 100% at 8 mg/L (Table 2). Tazobactam, at 4 mg/L, expanded the 122 
proportion of AmpC hyperproducers susceptible at 1 mg/L to 96.7%, but did not cause major MIC 123 
reductions.  By contrast tazobactam greatly potentiated cefepime against ESBL producers: whereas 124 
only 20.5% of producers were susceptible to unprotected cefepime at 1 mg/L, 94.9% were susceptible 125 
to cefepime/tazobactam 1+4 mg/L; similarly, 54.5% of ESBL producers were inhibited by cefepime at 8 126 
mg/L and 99.4% by cefepime/tazobactam 8+4 mg/L.   MICs for K. oxytoca hyperproducing K1 enzyme 127 
were reduced one or two doubling dilutions by tazobactam, but largely remained in the 2-8 mg/L range.      128 
 All Enterobacteriaceae with NDM carbapenemases were resistant to cefepime/tazobactam 8+4 129 
mg/L, as were 63% of those with KPC carbapenemases.  The behaviours of isolates with VIM and OXA-130 
48-like carbapenemases were more complex.  Sixty-five per cent (13/20) of isolates with VIM metallo-131 
carbapenemases were resistant to cefepime at 8 mg/L, but this proportion fell to 20% (4/20)  in the 132 
presence of 4 mg/L tazobactam, with 75% of MICs falling into the 2+4 to 8+4 mg/L range. All of the 133 
cefepime-resistant VIM-positive isolates that gained ‘susceptibility’ to cefepime/tazobactam were 134 
aztreonam resistant, based on previous testing, supporting the view that they co-produced further -135 
lactamases, probably ESBLs. For isolates with OXA-48-like enzymes the MIC distribution of 136 
unprotected cefepime was bimodal, with values clustered between 0.25 to 2 mg/L or above 32 mg/L, 137 
corresponding to the fact that OXA-48 itself does not attack these oxyimino-cephalosporins18 and that 138 
any resistance depends on co-produced enzymes, principally ESBLs (AmpC enzymes would have little 139 
effect on cefepime). With tazobactam added, cefepime MICs for the cefepime-resistant OXA-48 140 
producers were reduced into the 1-8 mg/L range, with only 1/25 values remaining >8 mg/L. 141 
 The expansion of anti-Enterobacteriaceae activity was impressive compared to both 142 
piperacillin/tazobactam and ceftazidime, particularly against isolates that did not have 143 
carbapenemases, where the overall spectrum of cefepime/tazobactam more closely resembled that of 144 
meropenem. Based on the CLSI criterion of >16+4 mg/L, non-susceptibility to piperacillin/ tazobactam 145 
was seen for 9/22 penicillinase-producers and 66/176 ESBL producers along with 71/91 AmpC 146 
producers and all the K. oxytoca hyperproducing K1 enzymes, whereas all these isolates, except for 147 
one ESBL producer, were susceptible to cefepime/tazobactam 8+4 mg/L.  Ceftazidime non-148 
susceptibility, based on CLSI’s  >2 mg/L criterion, was seen in more than 90% of isolates in most groups 149 
except (i) controls and penicillinase producers, (ii) K. oxytoca hyperproducing K1 -lactamase.    150 
Meropenem was active at the CLSI susceptible breakpoints (S <1 mg/L) against all the ESBL producers, 151 
K1 isolates and AmpC producers as well as control strains and penicillinase producers.  Comparator 152 
activity, like that of cefepime/tazobactam, was limited against carbapenemase producers. All were non-153 
susceptible to piperacillin/tazobactam, with ceftazidime susceptibility seen only for cefepime-154 
susceptible isolates with OXA-48-like enzymes. In the case of meropenem, isolates with NDM enzymes 155 
consistently were resistant whereas MICs for those with other enzyme type straddled breakpoints, with 156 
many OXA-48 isolates appearing meropenem susceptible at CLSI's S <1 mg/L criterion and with MICs 157 
of 2-8 mg/L for many with VIM metallo-enzymes. 158 
 159 
 Non-fermenters 160 
Addition of tazobactam caused little or no shift in the MIC distribution of cefepime for (i) P. aeruginosa 161 
with normal or up-regulated efflux, (ii) P. aeruginosa with MBLs, which were universally resistant, or (iii) 162 
Acinetobacter spp. with OXA carbapenemases.  Tazobactam did cause downward shifts in the MIC 163 
distributions of cefepime for P. aeruginosa with VEB and PER ESBLs, S. maltophilia and, more 164 
surprisingly, for Acinetobacter spp. with AmpC activity; only in the last of these cases, however, were 165 
cefepime MICs commonly shifted below 8 mg/L.  Most cefepime-susceptible Acinetobacter spp. were 166 
directly inhibited by tazobactam at 4 mg/L. 167 
 168 
In vitro dose-response effects 169 
The effect of raising the tazobactam to 8 mg/L rather than 4 mg/L, as routinely used, is illustrated for 170 
sub-sets of the Enterobacteriaceae isolates in Table 3.  Small additional downward shifts in MIC 171 
distributions, of around one doubling dilution, were seen were seen for many β-lactamase-producing 172 
groups, including those with AmpC, ESBL KPC, and K1 enzymes, though not for MBL-producing 173 
Enterobacteriaceae. MIC shifts for non-fermenter groups were minimal (not shown).  174 
 175 
Discussion 176 
Even at the most conservative likely breakpoint (1+4 mg/L), cefepime/tazobactam achieved good 177 
activity against Enterobacteriaceae with ESBLs and AmpC enzymes as well as those with acquired 178 
penicillinases. At 8+4 mg/L or 8+8 mg/L, corresponding to the upper edge of CLSI’s ‘dose-dependent 179 
susceptibility category’7 –susceptibility was seen also for most cefepime-resistant isolates with K1, 180 
OXA-48 and VIM enzymes. Against non-fermenters, cefepime/tazobactam essentially retained 181 
cefepime’s activity with only small further gains, notably against AmpC-producing Acinetobacter spp.  182 
This spectrum is impressive and exceeded that of unprotected cefepime, ceftazidime or 183 
piperacillin/tazobactam, more closely resembling meropenem.   184 
Ceftolozane/tazobactam was not included here, but is an obvious comparator.  The major 185 
difference between ceftolozane and cefepime, in relation to Enterobacteriaceae, is that ceftolozane is 186 
less stable to AmpC enzymes, which are poorly inhibited by tazobactam. Consequently, 187 
ceftolozane/tazobactam MICs for AmpC-derepressed Enterobacter spp. are mostly 4-8 mg/L, 188 
compared with 0.12 to 1 mg/L found for cefepime/tazobactam (Table 2).16,19 ESBL producers too were 189 
more often susceptible to cefepime/tazobactam, though less strikingly so. Thus, among isolates 190 
collected in the BSAC Bacteraemia Surveillance from 2011-2015 (inclusive) 97.9% of ESBL E. coli and 191 
86.5% of ESBL K. pneumoniae were susceptible to ceftolozane/tazobactam at 1+4 mg/L (the FDA and 192 
EUCAST Breakpoint)16 compared, here, with 98.3% (59/60) ESBL E. coli and 92.4% (73/79) ESBL K. 193 
pneumoniae susceptible to cefepime/tazobactam 1+4 mg/L and all except one K. pneumoniae 194 
susceptible at 8+4 mg/L.  The more consistent activity of cefepime/tazobactam against ESBL producers 195 
may relate to a shorter time above a concentration threshold being needed for tazobactam to protect 196 
cefepime than ceftolozane, at least for strains with CTX-M-15, which is the commonest ESBL.20,21  197 
Easier protection of cefepime, in turn, may depend on the molecule’s rapid permeation of Gram-198 
negative bacteria and its low affinity for some enzyme types22 and/or its greater affinity for PBP2, which 199 
may enhance cidality.23  However, there is insufficient information on these aspects for ceftolozane to 200 
allow definitive conclusions and it is it unclear if the shorter time needed above threshold for tazobactam 201 
to protect cefepime is specific to CTX-M-15 or is generalizable to other ESBLs.  Moreover, experience 202 
with piperacillin/tazobactam shows significant unexplained variation in susceptibility among ESBL 203 
producers, even when these have the same -lactamase(s) and belong to the same strain.24 204 
 The frequent activity of cefepime/tazobactam against Enterobacteriaceae with VIM MBLs is 205 
surprising but mirrors behaviour AMRHAI see with cefepime-clavulanate in reference testing (the 206 
combination is tested to detect ESBLs in AmpC-inducible species but also gets to be tested, 207 
gratuitously, against all Gram-negative submissions).  Since neither tazobactam nor clavulanate 208 
significantly inhibits metallo -lactamases,25 the likeliest explanation is that VIM enzymes themselves 209 
are only weakly active against cefepime and that resistance caused by co-produced ESBLs is 210 
substantially reversed by tazobactam or clavulanate.  In the case of strains with OXA-48-like enzymes, 211 
MICs of cefepime/tazobactam for most cefepime-resistant isolates were reduced into the 2+4 to 8+4 212 
mg/L range.  This incomplete potentiation may seem surprising, given that cefepime, like ceftazidime, 213 
evades OXA-48 like enzymes,18,26 with any resistance arising from co-produced ESBLs, which should 214 
be inhibited by tazobactam.  The behaviour may reflect isolates having multiple enzymes, permeability 215 
lesions or, speculatively, to OXA-48-like enzymes being able to inactivate tazobactam, as can KPC 216 
enzymes.27  Ceftolozane/tazobactam MICs for ceftazidime-resistant OXA-48 producers referred to 217 
AMRHAI are mostly higher than found here for cefepime/tazobactam, exceeding 16+4 mg/L in just over 218 
50% of cases.16 These data again support the view that cefepime is an easier molecule to protect. 219 
 In summary, these data, along with a 7891-isolate survey of consecutive Gram-negative bacilli 220 
from international sources,28 support the development of cefepime/tazobactam as a potential 221 
‘workhorse’ combination, potentially supplanting piperacillin/tazobactam – the present workhorse – and 222 
achieving similar coverage to a carbapenem against ESBL and AmpC-producing Enterobacteriaceae. 223 
There was also some activity –at least at cefepime’s ‘dose-dependent’ breakpoints- also against many 224 
strains with VIM and OXA-48-like carbapenemases.  Whilst unlikely to be preferred definitive therapy 225 
where strains with these enzymes are implicated, the combination may have sufficient activity not to be 226 
a major selector of these carbapenemases.   227 
 Given the propensity of bacteria to acquire complex batteries of β-lactamases, often copiously 228 
expressed, it seems prudent to use the highest levels of tazobactam that can be safely dosed – and 229 
certainly more than in the 8:1 cefepime/tazobactam preparations currently marketed in India. A 1:1 230 
combination (WCK 4282) has been proposed by Wockhardt and, in a Phase I trial, was well tolerated 231 
at up to 2+2g iv when given thrice daily, by 90 min infusion, for up to 7 days.10 Comparison to published 232 
data suggests that cefepime/tazobactam should achieve a wider spectrum than 233 
ceftolozane/tazobactam against problem Enterobacteriaceae, whereas the advantage against P. 234 
aeruginosa lies with ceftolozane/tazobactam, based on ceftolozane being inherently more active than 235 
cefepime (or ceftazidime) against this species.16 236 
 237 
Acknowledgements. 238 
We are grateful to all the PHE staff that contributed to characterisation of these isolates, also to Dr 239 
Linda Miller of GSK and Drs Mahesh Patel and Sachin Bhagwat of Wockhardt for helpful discussions. 240 
 241 
Funding 242 
Parts of this work have been funded by GlaxoSmithKline and by Wockhardt. 243 
 244 
Transparency declaration 245 
DML: Advisory Boards or ad-hoc consultancy Accelerate, Achaogen, Adenium, Allecra, AstraZeneca, 246 
Auspherix, Basilea, BioVersys, Centauri, Discuva, Inhibox, Meiji, Nordic, Pfizer, Roche, Shionogi, 247 
Tetraphase, VenatoRx, Wockhardt, Zambon, Zealand. Paid lectures – Astellas, AstraZeneca, 248 
Cardiome, Cepheid, Merck, Nordic and Pfizer.  Relevant shareholdings– Dechra, GSK, Merck, Perkin 249 
Elmer and Pfizer collectively amounting to <10% of portfolio value.   ST ad hoc consultancy for 250 
Wockhardt   All others: No personal interests to declare. However, PHE’s AMRHAI Reference Unit 251 
has received financial support for conference attendance, lectures, research projects or contracted 252 
evaluations from numerous sources, including: Accelerate, Achaogen, Allecra, Amplex, AstraZeneca, 253 
Basilea, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, The BSAC, Cepheid, Check-254 
Points, Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, 255 
GlaxoSmithKline, Henry Stewart Talks, IHMA, Kalidex, Melinta, Merck Sharpe & Dohme , Meiji, 256 
Mobidiag, Momentum Biosciences, Nordic, Norgine, Rempex, Roche, Rokitan, Smith & Nephew, Trius 257 
, VenatoRx and Wockhardt. 258 
References 259 
1. Paterson DL, Bonomo RA. Extended-spectrum -lactamases: a clinical update.  Clin Microbiol 260 
Rev 2005; 18:657-86. 261 
2. Livermore DM. Determinants of the activity of -lactamase inhibitor combinations. J 262 
Antimicrob Chemother 1993; 31 Suppl A:9-21. 263 
3. Payne DJ, Miller LF, Findlay D et al. Time for a change: addressing R&D and 264 
commercialization challenges for antibacterials. Philos Trans  R Soc Lond B Biol Sci 2015; 265 
370(1670):20140086. 266 
4. Livermore DM, Hope R, Mushtaq S . Orthodox and unorthodox clavulanate combinations 267 
against extended-spectrum -lactamase producers. Clin Microbiol  Infect 2008; 14 Suppl 268 
1:189-93.  269 
5. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious 270 
infections due to apparently susceptible organisms producing  extended-spectrum -271 
lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 272 
39:2206-12. 273 
6. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoints, available 274 
via http://www.eucast.org/clinical_breakpoints/ 275 
7. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial 276 
Susceptibility Testing: Informational Supplement M100S 26th Edition.  CLSI, Wayne, PA, 277 
USA, 2016 278 
8. Tärnberg M, Ostholm-Balkhed A, Monstein HJ et al. In vitro activity of lactam antibiotics 279 
against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011;30:981-7. 280 
9. Livermore DM, Canton R, Gniadkowski M et al.. CTX-M: changing the face of ESBLs in 281 
Europe. J Antimicrob Chemother 2007; 59:165-74. 282 
10. Bhatia A, Chungh R, Gupta M et alk. Safety, tolerability and pharmacokinetics of WCK 4282 283 
(FEP-TAZ) in healthy adult subjects. In Abstracts of the 26th European Congress of Clinical 284 
Microbiology and Infectious Diseases, Amsterdam, the Netherlands 2016.  Poster P1260 285 
11. Medline India, cefepime tazobactam 286 
http://www.medlineindia.com/antibiotic/cefepime_with_tazobactam.html 287 
12. Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/ 288 
tazobactam: A new -lactam/-lactamase inhibitor combination. J Microbiol Infect Dis 2012; 289 
2:79-86. 290 
13. Kaur K, Gupta A, Sharma A et al.  Evaluation of efficacy and tolerability of cefotaxime and 291 
sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective 292 
comparative study. J Clin Diagn Res 2014; 8:HC05-8. 293 
14. Papp-Wallace KM, Bonomo RA. New β-Lactamase Inhibitors in the clinic. Infect Dis Clin 294 
North Am 2016; 30:441-64. 295 
15. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, 296 
against carbapenem-resistant  Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 297 
66:48-53. 298 
16. Livermore DM, Mushtaq S, Meunier D et al. Activity of ceftolozane/tazobactam against 299 
surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-300 
fermenters from the British Isles. J Antimicrob Chemother 2107; 72: 2278-89. 301 
17. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility 302 
Tests for Bacteria that Grow Aerobically: Approved Standard M7-A9. CLSI, Wayne, PA, USA, 303 
2011. 304 
18. Poirel L, Héritier C, Tolün V et al. Emergence of oxacillinase-mediated resistance to 305 
imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:15-22. 306 
19. Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 307 
(FR264205) and tazobactam versus lactamase-producing Enterobacteriaceae. J 308 
Antimicrob Chemother 2010; 65:1972-4.  309 
20. VanScoy B, Mendes RE, McCauley J et al. Pharmacological basis of β-lactamase inhibitor 310 
therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 311 
2013;57:5924-30. 312 
21. VanScoy BD, Tenero D, Turner S et al. Pharmacokinetics-pharmacodynamics  of tazobactam 313 
in combination with cefepime in an in vitro infection model. Antimicrob Agents Chemother 314 
2017, in press.  315 
22. Hancock RE, Bellido F. Factors involved in the enhanced efficacy against Gram-negative 316 
bacteria of fourth generation cephalosporins. J Antimicrob Chemother 1992; 29 Suppl A:1-6. 317 
23. Davies TA, Page MG, Shang W et al. Binding of ceftobiprole and comparators to the 318 
penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus 319 
aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51:2621-4. 320 
24. Babini GS, Yuan M, Hall LM et al. Variable susceptibility to piperacillin/tazobactam amongst 321 
Klebsiella spp. with extended-spectrum -lactamases. J Antimicrob Chemother 2003; 51:605-322 
12. 323 
25. Ohsuka S, Arakawa Y, Horii T et al. Effect of pH on activities of novel -lactamases and -324 
lactamase inhibitors against these -lactamases. Antimicrob Agents Chemother 1995; 325 
39:1856-8. 326 
26. Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with β-327 
lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella 328 
pneumoniae. Int J Antimicrob Agents 2012; 39:86-9. 329 
27. Papp-Wallace KM, Bethel CR, Distler AM et al. Inhibitor resistance in the KPC-2 -lactamase, 330 
a preeminent property of this class A -lactamase. Antimicrob Agents Chemother 2010; 331 
54:890-7. 332 
28. Sader HS, Castanheira M, Mendes RE et al. Antimicrobial activity of high-proportion 333 
cefepime/tazobactam (WCK 4282) against a large number of Gram-negative isolates 334 
collected worldwide in 2014. Antimicrob Agents Chemother 2017; 61: pii: e02409-16. 335 
Table 1.  Genus distribution among Enterobacteriaceae panels 336 
 Citrobacter Enterobacter Escherichia Klebsiella Morganella Proteus Providencia Serratia Total 
Susceptible controls 16 20 10 10 10 10  10 86 
Penicillinase   10 12     22 
ESBL 4 20 60 79 2 11   176 
K. oxytoca hyperproducing K1    20     20 
AmpC 15 20 18 18 10   10 91 
KPC  10 10 21     41 
OXA-48   5 20     25 
NDM 1 4 5 10 1  4  25 
VIM  5 5 10     20 
Total 36 79 123 200 23 21 4 20 506 
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Table 2.  Comparative activity of cefepime/tazobactam 4 mg/L against isolate panels 339 






Enterobacteriaceae <0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 1+4 8+4 
Susceptible controls (86) 
   Cefepime 42 31 8 5           100 100 
   Cefepime/tazobactam 4 mg/L 44 28 9 5           100 100 
   Ceftazidime  11 12 25 32 6         - - 
   Piperacillin/tazobactam 4 mg/L   11* 4 6 1 41 19 3 1     - - 
   Meropenem 55 22 4 5           - - 
Penicillinase producers (22) 
   Cefepime 2 9 5 4 1 1         100 100 
   Cefepime/tazobactam 4 mg/L 9 5 6 1 1          100 100 
   Ceftazidime   2 12 8          - - 
   Piperacillin/tazobactam 4 mg/L      4 5 1 3  1 2  6 - - 
   Meropenem 21 1             - - 
AmpC hyperproducers (91) 
   Cefepime 4 4 12 10 24 20 14 3       81.3 100 
   Cefepime/tazobactam 4 mg/L 7 9 23 21 18 10 3        96.7 100 
   Ceftazidime      5 1 3 3 13 15 29 18 4 - - 
   Piperacillin/tazobactam 4 mg/L    2 4  2 3 9 16 25 17 8 5 - - 
   Meropenem 30 39 13 9           - - 
ESBL producers (176) 
   Cefepime  2 2 2 9 21 31 19 10 21 12 13 11 23 20.5 54.5 
   Cefepime/tazobactam 4 mg/L 19 55 37 34 18 4 1 5 2   1   94.9 99.4 
   Ceftazidime    2 3 12 14 15 3 7 27 31 34 28 - - 
   Piperacillin/tazobactam 4 mg/L   4  5 6 31 40 24 28 14 5 3 16 - - 
   Meropenem 124 42 6 2  2         - - 
K1 hyperproducing K. oxytoca (20) 
   Cefepime     1 3 1 8 6  1    20 95 
   Cefepime/tazobactam 4 mg/L    1 2 1 11 4 1      20 100 
   Ceftazidime     4 4 10 2       - - 
   Piperacillin/tazobactam 4 mg/L              20 - - 
   Meropenem 5 12 3            - - 
KPC producers (41) 
   Cefepime       1 1 3 5 2 3 7 19 0 12.2 
   Cefepime/tazobactam 4 mg/L      2 4 5 4 7 6 5 5 3 4.9 36.3 
   Ceftazidime        1 7 3 7 7 4 12 - - 
   Piperacillin/tazobactam 4 mg/L            1 2 38 - - 
   Meropenem      1 2 5 6 4 10 1 5 7 - - 
OXA-48 -lactamase producers (25) 
   Cefepime    7 2 3 1  1  1 5 3 2 48.0 56.0 
   Cefepime/tazobactam 4 mg/L   4 4 2 2 7 4 1 1     48.0 96.0 
   Ceftazidime   1 6 4 2 1 3    4 3 1 - - 
   Piperacillin/tazobactam 4 mg/L             3 22 - - 
   Meropenem  1   5 11 3 1  1 3    - - 
NDM -lactamase producers (25) 
   Cefepime          1 3 5 1 15 0 0 
   Cefepime/tazobactam 4 mg/L         1 2 7 6 3 6 0 0 
   Ceftazidime              25 - - 
   Piperacillin/tazobactam 4 mg/L            1 1 23 - - 
   Meropenem        1 2 2 11 6 1 2** - - 
VIM -lactamase producers (20) 
   Cefepime    1   3 1 2 5 1 4 3  5 35 
   Cefepime/tazobactam 4 mg/L    1  2 7 2 4   2 2  15 80 
   Ceftazidime         1 1  3 4 11 - - 
   Piperacillin/tazobactam 4 mg/L           1   19 - - 
   Meropenem      2 4 8 4 2     - - 
                 
 <0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64 128 >128 1+4 8+4 
P. aeruginosa 
Normal /upregulated efflux (30)                 
   Cefepime  1    1 9 5 8 5 1    - 80 
   Cefepime/tazobactam 4 mg/L  1    4 6 5 8 5 1    - 80 
   Ceftazidime 1     3 12 4 5 5     - - 
   Piperacillin/tazobactam 4 mg/L   1*  2  1 6 7 1 11 1   - - 
   Meropenem  2 3 1 8 4 4 2 2 3 1    - - 
ESBL producers (7 PER, 3 VEB) 
   Cefepime           1 4 2 3 - 0 
   Cefepime/tazobactam 4 mg/L       1   2 3 4   - 10 
   Ceftazidime              10 - - 
   Piperacillin/tazobactam 4 mg/L     1   1 2  2 2 2  - - 
   Meropenem    1 3  1 3 1  1    - - 
                 
MBL producers (5 IMP, 5 VIM) 
   Cefepime           1 2 1 6 - 0 
   Cefepime/tazobactam 4 mg/L          1 1 1 2 4 - 0 
   Ceftazidime           1 1 3 5 - - 
   Piperacillin/tazobactam 4 mg/L          2 1 2 2 3 - - 
   Meropenem        1   1 2 2 4 - - 
                 
Acinetobacter baumannii 
Control strains (7) 
   Cefepime      2 5        - 100 
   Cefepime/tazobactam 4 mg/L 7              - 100 
   Ceftazidime       
6 1 
      - - 
   Piperacillin/tazobactam 4 mg/L   6  1          - - 
   Meropenem  1  5 1          - - 
AmpC producers (10) 
   Cefepime        1  4 4   1 - 10 
   Cefepime/tazobactam 4 mg/L      2  2 2 3   1  - 60 
   Ceftazidime        1  1 1 1 5 1 - - 
   Piperacillin/tazobactam 4 mg/L       1 1   1 2 4 1 - - 
   Meropenem    1  5 2 2       - - 
OXA carbapenemase producers (10) 
   Cefepime           4 4 1 1 - 0 
   Cefepime/tazobactam 4 mg/L         1 2 4 2  1 - 10 
   Ceftazidime         1 2  1 2 4 - - 
   Piperacillin/tazobactam 4 mg/L          2 1   7 - - 
   Meropenem        1  3 4 2   - - 
S. maltophilia                 
   Cefepime         1 2 2 4  1 - 10 
   Cefepime/tazobactam 4 mg/L        1 3  5  1  - 40 
   Ceftazidime        1 1 2  3 1 2 - - 
   Piperacillin/tazobactam 4 mg/L           2   8 - - 
   Meropenem           1 3 4 2 -  
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Table 3.  Dose response effect of tazobactam at 4 or 8 mg/L in potentiating cefepime 342 
Group and tazobactam 
concentration, mg/L 
No isolates with indicated MIC (mg/L) 
<0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 >256 
Susceptible controls (25)                
0 12 7 4 2            
4 14 4 5 2            
8 12 7 4 2            
AmpC (34)                
0 2 2 5 4 7 6 5 3        
4 4 2 11 4 4 6 3         
8 5 8 8 2 7 4          
ESBL (35)                
0     2 4 9 3 1 4 1 3  1 7 
4 4 12 4 7 2 3  2    1    
8 5 14 7 4 2 2 1         
K. oxytoca K1 (5)                
0     1 3  1        
4    1 2  2         
8   1  3 1          
KPC (30)                
0       1 1 3 5 2 3 7 2 6 
4      2 4 5 4 6 5 2 2   
8     1 2 4 4 6 6 3 2 2   
OXA-48 (15)                
0    3 1 3     1 5 1  1 
4   2 2 1 2 4 2 1 1      
8    4  6 4  1       
NDM (20)                
0          1 3 3  5 8 
4         1 1 6 4 2 6  
8         1 1 6 4 2 6  
VIM (15)                
0    1    1 2 3 1 4 3   
4    1   4 2 4   2 2   
8    1   4 3 3    4   
 343 
